This company listing is no longer active
SYNLAB Balance Sheet Health
Financial Health criteria checks 4/6
SYNLAB has a total shareholder equity of €2.4B and total debt of €924.8M, which brings its debt-to-equity ratio to 39%. Its total assets and total liabilities are €4.7B and €2.3B respectively. SYNLAB's EBIT is €151.2M making its interest coverage ratio 1.8. It has cash and short-term investments of €300.5M.
Key information
39.0%
Debt to equity ratio
€924.83m
Debt
| Interest coverage ratio | 1.8x |
| Cash | €300.47m |
| Equity | €2.37b |
| Total liabilities | €2.34b |
| Total assets | €4.71b |
Recent financial health updates
No updates
Recent updates
SYNLAB (FRA:SYAB) Might Have The Makings Of A Multi-Bagger
Dec 15
Returns Are Gaining Momentum At SYNLAB (FRA:SYAB)
Sep 10SYNLAB AG (FRA:SYAB) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 14SYNLAB AG (FRA:SYAB) Stock Catapults 27% Though Its Price And Business Still Lag The Market
May 29SYNLAB (FRA:SYAB) Is Investing Its Capital With Increasing Efficiency
May 20Are Investors Undervaluing SYNLAB AG (FRA:SYAB) By 25%?
Sep 26Shareholders Will Be Pleased With The Quality of SYNLAB's (FRA:SYAB) Earnings
Aug 22Financial Position Analysis
Short Term Liabilities: SYAB's short term assets (€860.3M) exceed its short term liabilities (€693.9M).
Long Term Liabilities: SYAB's short term assets (€860.3M) do not cover its long term liabilities (€1.6B).
Debt to Equity History and Analysis
Debt Level: SYAB's net debt to equity ratio (26.3%) is considered satisfactory.
Reducing Debt: SYAB's debt to equity ratio has reduced from 248.8% to 39% over the past 5 years.
Debt Coverage: SYAB's debt is well covered by operating cash flow (45.3%).
Interest Coverage: SYAB's interest payments on its debt are not well covered by EBIT (1.8x coverage).